RecruitingPhase 3NCT05643872
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
Studying Pachyonychia congenita
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Palvella Therapeutics, Inc.
- Intervention
- PTX-022(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- Minnesota Clinical Study Center, New Brighton, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05643872 on ClinicalTrials.govOther trials for Pachyonychia congenita
Additional recruiting or active studies for the same condition.